University of Virginia School of Medicine scientists have obtained important new insights into how our bodies regulate our ...
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) said its Phase 3 Launch-HTN clinical trial evaluating lorundrostat ...
NCX 470 is currently licensed to Ocumension Therapeutics for China, Korea, and Southeast Asia. According to Nicox, projected ...
Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant ...
Thrombocytopenia in chronic liver disease arises from a variety of factors related to liver disease etiology, progression, and treatment. It is common in patients with cirrhosis and is a distinctive ...
A Penn-led team has revealed how hydralazine, one of the world's oldest blood pressure drugs and a mainstay treatment for preeclampsia, works at the molecular level. In doing so, they made a ...
GOTHENBURG, Sweden, Nov. 10, 2025 /PRNewswire/ -- Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare ...
Thrombocytopenia in chronic liver disease arises from a variety of factors related to liver disease etiology, progression, and treatment. It is common in patients with cirrhosis and is a distinctive ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback